| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
David Lamond is Director at QNCX. David Lamond's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $74.5M at current prices.
Our model assigns David Lamond a middling insider score of 66/100, based on 15 past trades. Over a 12-month horizon, 60.0% of those trades were profitable, with an average 12-month return of +35.5%.
Net of sales, the QNCX filings show accumulation of 694,209 shares.
David Lamond has 22 Form 4 filings on record from May 2019 to June 2026, across 2 companies: Director at IRulya Therapeutics (IRLA), 2026; Quince Therapeutics (QNCX), 2019–2026.
The 46 reported transactions were 32 open-market purchases, 9 option or other derivative awards, 2 stock awards and 2 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 9 purchases worth about $8.7M and no sales.
The largest open-market purchase was 44,648 shares of QNCX at an average $55.35 on May 19, 2020, about $2.5M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 14, 2023 | QNCX Quince Therapeutics, Inc. | Director | Buy | 67,881 | $1.02 | $69,232.62 | +3.0% | +14.6% | +97.1% | |
| Dec 7, 2023 | QNCX Quince Therapeutics, Inc. | Director | Buy | 57,369 | $1.01 | $58,133.92 | +2.6% | +17.0% | +110.0% | |
| Dec 1, 2023 | QNCX Quince Therapeutics, Inc. | Director | Buy | 43,134 | $0.94 | $40,545.96 | +2.0% | +35.4% | +113.5% | |
| Aug 31, 2023 | QNCX Quince Therapeutics, Inc. | Director | Buy | 82,052 | $1.32 | $107,898.38 | +3.9% | -28.2% | -47.3% | |
| Aug 17, 2023 | QNCX Quince Therapeutics, Inc. | Director | Buy | 250,000 | $1.30 | $325,736.58 | +13.5% | -29.9% | -56.8% | |
| Mar 24, 2021 | QNCX Quince Therapeutics, Inc. | Director | Buy | 50,000 | $33.77 | $1,688,500.00 | +2.8% | +68.3% | -81.4% | |
| Mar 4, 2021 | QNCX Quince Therapeutics, Inc. | Director | Buy | 50,000 | $35.34 | $1,767,057.34 | +2.9% | - | - | |
| Jun 4, 2020 | QNCX Quince Therapeutics, Inc. | Director | Buy | 49,125 | $43.27 | $2,125,794.96 | +2.9% | - | - | |
| May 19, 2020 | QNCX Quince Therapeutics, Inc. | Director | Buy | 44,648 | $55.35 | $2,471,251.33 | +2.7% | - | - |